The comprehensive characterization of a large number of cancer genomes will eventually lead to a compendium of genetic alterations in specific cancers. Unfortunately, the number and complexity of identified alterations complicate endeavors to identify biologically relevant mutations critical for tumor maintenance because many of these targets are not amenable to manipulation by small molecules or antibodies. RNA interference provides a direct way to study putative cancer targets; however, specific delivery of therapeutics to the tumor parenchyma remains an intractable problem. We describe a platform for the discovery and initial validation of cancer targets, composed of a systematic effort to identify amplified and essential genes in human cancer cell lines and tumors partnered with a novel modular delivery technology. We developed a tumor-penetrating nanocomplex (TPN) that comprised small interfering RNA (siRNA) complexed with a tandem tumor-penetrating and membrane-translocating peptide, which enabled the specific delivery of siRNA deep into the tumor parenchyma. We used TPN in vivo to evaluate inhibitor of DNA binding 4 (ID4) as a novel oncogene. Treatment of ovarian tumorbearing mice with ID4-specific TPN suppressed growth of established tumors and significantly improved survival. These observations not only credential ID4 as an oncogene in 32% of high-grade ovarian cancers but also provide a framework for the identification, validation, and understanding of potential therapeutic cancer targets.
INTRODUCTION
Genome-scale studies of cancer samples have begun to provide a global depiction of genetic alterations in human cancers, but the complexity and volume of data that emerge from these efforts have made dissecting the underlying biology of cancer difficult, and little is known about the functions of most of the candidates that emerge. For example, in studies of 489 primary high-grade serous ovarian cancer genomes, 1825 genes were identified as targeted by recurrent amplification events (1) . Systematic approaches to study the function of genes in cancer cell lines, such as genome-scale pooled short hairpin RNA (shRNA) screens, offer a means to assess the consequences of the genetic alterations found in such genome characterization efforts. We recently used an shRNA-based approach to find genes that are both overexpressed in human primary tumors and essential for the proliferation of ovarian cancer cells (2) . This approach identified 54 overexpressed and essential genes in ovarian cancer and 16 genes in non-small cell lung cancer that required further validation in vivo.
Furthermore, many of these candidates represent targets that are not amenable to antibody-based therapeutics or traditional small molecule approaches. Thus, if one envisions a discovery pipeline that begins with cancer genomes and ends with novel therapeutics, there is a bottleneck at the point of in vivo validation of novel targets.
Achieving silencing in the epithelial cells in the tumor parenchyma is especially critical to study the genetic alterations of interest. RNA interference (RNAi) is a potentially attractive means to silence the expression of candidate genes in vivo, particularly for undruggable gene products (3, 4) . However, systemic delivery of small interfering RNA (siRNA) to tumors has been challenging, owing to rapid clearance, susceptibility to serum nucleases, and endosomal entrapment of small RNAs, in addition to their inherent inadequate tumor penetration (5) . Tumor penetration is also a problem for the delivery of siRNA and shRNA, among other cargos, and is characterized by limited transport into the extravascular tumor tissue beyond the perivascular region (6) . This low penetration is thought to arise from the combination of dysfunctional blood vessels that are poorly perfused and a high interstitial pressure, especially in solid tumors, in part due to dysfunctional lymphatics (7) . The leakiness of tumor vessels partially counteracts the poor penetration [the so-called enhanced permeability and retention (EPR) effect], but the size dependence and variability of this property can limit its usefulness (7) . Desmoplastic stromal barriers can further impede transport of therapeutics through tumors (8, 9) .
A new class of tumor-penetrating peptides has been described recently, which home to several types of tumors and leverage a consensus R/KXXR/K C-terminal peptide motif [the C-end rule (CendR)] to stimulate transvascular transport and rapidly deliver therapeutic cargo deep into the tumor parenchyma (10, 11) . These peptides are tumorspecific, unlike canonical cell-penetrating peptides (CPPs) that do not display cell-or tissue-type specificity (12) , and are able to improve the delivery of small molecules, antibodies, and nanoparticles (13) . Despite their promise, this class of peptides has not been successfully co-opted for siRNA delivery, in part owing to the additional challenges of delivering oligonucleotides across cell membranes, out of endosomes, and into the cytosol to achieve gene silencing.
Here, we designed an siRNA delivery vehicle that was tumorpenetrating and modular, so it could be easily assembled in a single step to accommodate different payloads to various genes of interest. We envision that such a technology would enable a platform wherein novel targets can be identified by structural and functional genomics and subsequently rapidly credentialed both in vitro and in vivo. Followup studies could then identify the mechanism of action underlying the observations and establish (and ultimately prioritize) novel oncogenes as therapeutic targets. To achieve this goal, we have combined a systematic effort to identify genes that are both essential and genetically altered in human cancer cell lines and tumors with the development and deployment of a novel tumor-specific and tissue-penetrating siRNA delivery platform.
RESULTS
Identification of ID4 as an essential oncogene in human ovarian cancer To facilitate the identification of genes that are essential in specific cancer types, we initiated Project Achilles, a large-scale effort involving genome-scale pooled shRNA screens in human cancer cell lines (2) . Recent efforts to characterize the genomes of primary high-grade serous ovarian cancer have revealed 63 recurrent regions of copy number gain and 50 regions of copy number loss, each containing several genes (1) . To identify genes that are both recurrently amplified and essential in ovarian cancers that harbor increased copy number of these genes, we quantified the distribution of shRNA proliferation scores among all shRNAs for each amplified gene (Fig. 1A) . We identified 206 cases in which shRNAs targeting the amplified gene were significantly depleted (P < 0.05, z score), including known ovarian cancer oncogenes KRAS, AKT1, BCL2L1, and ERBB3, and newer candidates for ovarian cancer, including the inhibitor of DNA binding 4 (ID4) transcriptional regulatory protein and the S-phase kinase-associated protein 2 (SKP2) E3-ubiquitin ligase (table S1) .
We selected ID4, a helix-loop-helix (HLH) transcriptional regulator, for further study because recent genomic analyses have indicated that the chromosomal region containing ID4 (6p22) is amplified in 32% of high-grade serous ovarian cancers (1) (Fig. 1B) . Also, ID4 is overexpressed in most primary ovarian cancers but not in normal ovary, fallopian tube (FT), and other tissues ( Fig. 1C and fig. S1A ). In addition, by examining the transcript levels of ID4 in a large panel of cancer cell lines, we found that ID4 was frequently overexpressed in most ovarian cancer cell lines and cell lines derived from other cancer lineages, such as endometrial cancer, breast cancer, and glioblastoma (fig. S1B).
After identifying ID4 as a candidate oncogene in human samples, our next step was to establish preclinical models to credential the oncogenic potential of ID4, specifically by investigating the relationship between the amplification, expression, and essentiality of ID4 in a panel of human cancer cell lines. First, we found that multiple shRNAs that did not alter the expression of ID1, ID2, and ID3, but suppressed ID4 ( fig. S1C) , significantly inhibited the proliferation of 9 of 11 ovarian cancer cell lines and two glioblastoma cell lines tested (range, 53 to 92%) (Fig. 1D ). Ovarian cancer cell lines OVCAR-8, OVCAR-4, and CaOV-3, which harbor increased copy number (Fig. 1E ) and exhibit overexpression of ID4 (Fig. 1D) , died by apoptosis after ID4 suppression ( fig. S1D ). By contrast, seven cell lines that express comparatively lower ID4 levels showed little inhibition of proliferation after ID4 suppression (range, 0 to 44%) (Fig. 1D) .
We then tested whether ID4 was an oncogene by investigating its ability to induce cell transformation. Expression of oncogenic HRAS V12 or coexpression of known RAS effectors renders immortalized human epithelial cells tumorigenic in vivo (14) . Therefore, to investigate the role of ID4 in human ovarian epithelial cells, we similarly created an ovarian surface epithelial cell line [IOSE-M (immortalized ovarian surface epithelial) cells] expressing SV40 large T and small t antigens, hTERT (human telomerase reverse transcriptase), and MEK DD (a constitutively active mutant of a mitogen-activated or extracellular signalregulated protein kinase kinase) ( fig. S1E) , and used this cell line to identify genes that promote tumorigenicity. Expression of ID4 at levels found in ovarian cancer cell lines did not affect the cell cycle progression (fig. S1F) but markedly increased the rate of tumor formation in vivo compared to cells expressing a control vector (Fig. 1F) . Addition of ID4 that harbored mutations in the HLH domain or the addition of ID1, ID2, or ID3 each failed to confer significant tumorigenicity (Fig. 1F) .
Recent work suggests that most ovarian cancers arise from the FT epithelium rather than the ovarian surface epithelium (15) . Hence, we used immortalized FT epithelial cells (16) and assessed whether ID4 expression also induced cell transformation in these cells. As we found for ovarian epithelial cells, ID4 induced anchorage-independent growth in FT cells (Fig. 1G ). These observations show that ID4 is amplified, essential, and transforming in ovarian epithelial cells.
ID4-induced transformation through regulation of the HOXA9 and CDKN1A transcriptional programs To explore the mechanism of action by which ID4 induces transformation, we performed gene expression profiling in IOSE-M cells that overexpress ID4 or a control vector. Among the top five gene sets, we found significant enrichment of three gene sets up-regulated by expression of the oncogenic Nucleoporin 98-Homeobox A9 (NUP98-HOXA9) fusion protein (17) (Fig. 2A and fig. S2 ). These three gene sets represent short-term (6 hours) and long-term (3 and 8 days) up-regulation after induction of NUP98-HOXA9. ID4 expression in IOSE-M cells consistently increased the expression of multiple HOXA genes, including HOXA9, HOXA7, and HOXA3 (Fig. 2B) , whereas suppression of ID4 led to significantly reduced levels of these same genes ( Fig. 2C and fig. S3A ). To determine whether HOXA9 was required for ID4-induced cell transformation, we introduced three previously validated HOXA9-specific shRNAs (18) or control shRNAs targeting green fluorescent protein (shGFP) into ID4-overexpressing IOSE-M cells ( fig.  S3B ). Suppression of HOXA9 only slightly (~30%) reduced cell proliferation ( fig. S3C ) but significantly inhibited ID4-induced anchorageindependent growth (Fig. 2D ) and reduced the rate of tumor formation in vivo compared to control shGFP (Fig. 2E) .
Finally, to confirm these observations in human ovarian cancers, we analyzed the expression profiles from primary ovarian tumors by The Cancer Genome Atlas (TCGA) project (1) and found that many genes within the NUP98-HOXA9 expression signature (TAKEDA_ TARGETS OF NUP98-HOXA9 FUSION_10D_DN) were significantly -I  TOV-21G  A2780  SKOV-3  OV-90  TOV-112D  U251-MG  LN-229  HCC827  H1650  MCF-7  T47D  DLD-1   shID4#2  Control shRNAs  shID4#1   OVCAR-8  OVCAR-4  CaOV-3  IGROV1  NIH:OVCAR-3  RMG-I  TOV-21G  A2780  SKOV-3  OV-90  TOV-112D  U251-MG  LN-229  HCC827  H1650  MCF-7  T47D  DLD- -expressing IOSE-M cells were used as a positive control. ***P < 0.001, Fisher's exact test; n.s., not significant. (G) ID4 promotes anchorageindependent growth of IOSE-M (ovarian epithelial) and FTSEC-M (FT) cells. Data are averages ± SD (n = 6). **P < 0.01, ***P < 0.001 compared to respective vector control, Student's t test.
down-regulated in tumors that express low levels of ID4 (Fig. 2F) (20) . Once bound, LyP-1 is proteolytically processed by endogenous proteases to reveal a cryptic CendR motif that activates tissue penetration of associated payloads and results in higher therapeutic accumulation (11, 21) . We postulated that a tandem peptide consisting of an N-terminal CPP with a C-terminal LyP-1 separated by a four-glycine linker domain would retain membrane translocation and tissue-penetrating properties, condense siRNA into nanoparticles, and selectively target tumor cells expressing p32 at the surface. We created a library of 18 linear membrane translocation domains that contained both polycationic peptide sequences [oligoarginines of varying net charge, TAT(48-60), and the herpes simplex virus type 1 tegument protein VP22] and amphipathic sequences [penetratin (PEN) and transportan (TP)]. Inspired by nonenveloped RNA viruses (22) , a myristoyl group was added to the amino terminus to facilitate interactions with membrane lipids (Fig. 3B and  fig. S4A ). We first confirmed that peptides from the library bound siRNA electrostatically to form stable nanocomplexes in water (diameter,~80 nm), phosphate-buffered saline (PBS, diameter~200 to 400 nm), and serum (diameter,~200 to 400 nm) ( fig. S4 , B and C). Most peptides (G) ID4 amplification in ovarian tumors correlated with decreased p21 WAF1/CIP1 activity. Expression profiling of primary ovarian tumors with matched copy number data was used to perform GSEA on amplified ID4 (log 2 copy number ratio >0.3) and nonamplified ID4 samples (log 2 copy number ratio <0). All genes were ranked by their differential expression (signal to noise) between 81 nonamplified and 109 amplified ID4 primary tumors. Black bars at the bottom of the figure indicate the location of genes in the p21 were noncytotoxic, with the exception of highly cationic peptides 12R and 15R ( fig. S4D ).
To evaluate nanocomplex-mediated gene silencing, we treated HeLa cells expressing destabilized GFP with siRNA targeting GFP (siGFP) bound to either tandem peptides or Lipofectamine. The top three carriers-6R, 9R, and TP-silenced GFP expression 40 to 60% (Fig. 3C) . Flow cytometry analysis indicated that gene suppression was dose-dependent and heterogeneous across the cell population, with 50 to 70% of cells exhibiting near-complete gene suppression ( fig. S4E) , with variation likely owing to heterogeneity in p32 expression. GFP suppression can underreport the magnitude of silencing endogenous gene targets, such as amplified oncogenes (23); thus, we used this assay to compare peptides but not as a quantitative measure of efficiency of RNAi of oncogenes. We chose nanocomplexes consisting of siRNA bound to TP-LyP-1 for further analysis [hereinafter referred to as the tumorpenetrating nanocomplex (TPN)] because it had the highest efficacy in delivering siRNA to cells, was potent relative to other tandem peptides (>25% gene suppression at 25 nM siRNA), and has a known secondary structure (24) , in contrast to poly-Arg peptides.
Next, we examined the specificity of receptor targeting and gene suppression. Uptake of LyP-1-targeted nanocomplexes was significantly higher than control nanocomplexes bearing ARAL (ARALPSQRSR), a peptide that has the same net charge as LyP-1 ( fig. S4F ). LyP-1 targeting was specific, as shown by competition assays with free LyP-1 ( fig.  S4G ) and in cells lacking the p32 receptor ( fig. S4H ). We did not detect statistically significant alterations in GFP expression in HeLa cells exposed to untargeted control nanocomplexes (UCNs) carrying siGFP (TP-ARAL/siGFP) or targeted TP-LyP-1 carrying a scrambled siRNA sequence (TP-LyP-1/siUT) (Fig. 3D) . In contrast, when we used TP-LyP-1 carrying siGFP, we observed more than 40% suppression of GFP expression. The tandem peptide construct and various membrane translocation domains tested. (C) Gene silencing activity of tandem peptide-siGFP nanocomplexes in HeLa cells stably expressing GFP. Percent GFP silencing was calculated on the basis of the geometric mean of GFP fluorescence intensity of the whole population relative to cells treated with media only. The Lipofectamine control (Lipo) contained 100 nM GFP-siRNA. Data are averages ± SD (n = 4 independent experiments). Inset: HeLa cell uptake of fluorescently labeled nanocomplexes was assessed by flow cytometry. Data are averages ± SD (n = 4 independent experiments). (D) Receptor specificity of nanocomplexmediated GFP silencing. Data are averages ± SD (n = 6 independent experiments). **P < 0.01, ***P < 0.001, one-way analysis of variance (ANOVA).
OVCAR-4 and OVCAR-8 human ovarian cancer cell lines have elevated surface p32 expression (fig. S5) ; therefore, these cell lines were compatible for testing TPN-mediated delivery of ID4-specific siRNA (siID4). When ID4 was suppressed in these cell lines in vitro using TPN (Fig. 4A ), we observed a decrease in cell viability ( Fig. 4B ) and an increased rate of apoptosis ( Fig. 4C and fig. S5 ). We therefore selected the OVCAR-4 and OVCAR-8 ovarian cancer cell lines for our preclinical evaluation of ID4 in vivo.
TPN homing and penetration in vivo in mice For in vivo applications, an ideal carrier should extend the half-life of siRNA in serum by protecting it from nuclease degradation, yet readily dissociate from siRNA once in the cytosol of target cells. We used a gel-shift assay to determine an optimal siRNA-to-peptide complexation molar ratio of 1:20, at which free siRNAs were encapsulated into TPN, likely owing to charge-based interactions between the peptide and the siRNA backbone (Fig. 5A ). We found that TPN extended the stability of siRNA to >12 hours in murine serum (Fig. 5A) , and the size of TPN remained stable in the presence of serum over the course of 10 hours (Fig. 5B) . Furthermore, we observed unpackaging of TPN upon exposure to endolysosomal pH (5.3 to 6.5) (Fig. 4D) .
We assessed whether TPN enabled receptor-specific, tumor-penetrating siRNA delivery to established tumors ( Fig. 5C ) by examining their in vivo homing behavior in mice bearing subcutaneous human melanoma tumors (MDA-MB-435 xenografts). After intravenous administration, most siRNAs were cleared renally, as indicated by bladder accumulation of siRNA over 8 hours ( fig. S6A ). However, we also observed that TPN was cleared more slowly than naked siRNA ( Fig. 5D ) and distributed to tumor tissues within 30 min ( fig. S6B ). We noted similar pharmacokinetics for intravenous and intraperitoneal injections of TPN, suggesting the potential for multiple routes of administration ( Fig. 5D and fig. S6A ).
Biodistribution studies showed blood clearance through liver and spleen accumulation, likely owing to reticuloendothelial uptake. TPN also distributed to the lung (fig. S6, C and D), a common uptake site for passively targeted nanoparticles, owing to interactions with the first capillary bed after intravenous injection (25) . After clearance from circulation (4 hours), we found a more than threefold increase in the tumor fluorescence of TPN in MDA-MB-435 xenografts compared to that of UCNs ( Although bulk tumor accumulation provides a global measure of targeting, it does not provide spatial information on the extravascular and tumor interstitial availability of TPN, which ultimately determines their efficacy. We thus performed histological characterization of TPN penetration in xenografted subcutaneous OVCAR-8 tumors at various time points and found that these TPN exhibited an initial intravascular distribution and subsequently extravasated into the tumor interstitium (Fig. 5F ). The fraction of TPNs that were sequestered beyond the intravascular space was significantly higher than that of UCNs (Fig. 5F ). Furthermore, TPNs accumulated in the tumor parenchyma to a degree similar to that of nanocomplexes bearing a different tumorpenetrating motif, immobilized arginine-glycine-aspartate (iRGD) (CRGDKGPDC) (10) . Nonpenetrating, targeted nanocomplexes (TP-RGD4C) (26) or the commercial reagent Lipofectamine failed to show a similar distribution (Fig. 5G ). We also found that TPN also colocalized with p32-positive tumor cells, as expected, but failed to detect UCNs or naked siRNAs in tumors ( fig. S6F ). This pattern of distribution is Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI). Tumor vasculature is CD31 + . Scale bars, 50 mm. Right: Extravascular and intravascular fractions of TPN were quantified from the fluorescence images. Data are averages ± SD, from representative sections of six independent tumors. ***P < 0.001 by two-tailed Student's t test. (G) Tumor parenchyma penetration by TPN with LyP-1 and iRGD homing domains, nonpenetrating nanocomplex targeted by RGD4C peptide, and Lipofectamine. Nanocomplexes were injected intravenously, and OVCAR-8 tumors were stained 1 or 3 hours later (n = 6 per formulation). Scale bars, 50 mm. Right: Tumor fluorescence was quantified. Data are averages ± SD from six randomly selected views per condition. **P < 0.01, ***P < 0.001, one-way ANOVA with Tukey post hoc tests. similar to previously reported LyP-1 peptide (21) and LyP-1-targeted nanoparticle homing (27) .
Loss of tumor maintenance after TPN-mediated suppression of ID4 in vivo We next tested whether ID4 was essential for tumor maintenance through TPN-mediated delivery of siID4 in established human ovarian cancer xenografts in vivo. Mice harboring subcutaneous OVCAR-4 tumors were injected intravenously or intraperitoneally with TPN/siID4 every 3 days for 25 days. Control animals with tumors were injected intravenously with saline, TP-LyP-1 carrier without siRNA, or TPN/siGFP. Repeated, systemic administration of the TPN/siID4 resulted in 80 to 90% decrease in ID4 mRNA relative to treatment with TPN/siGFP (Fig. 6A) , with a corresponding suppression of tumor growth by 82% in intravenously injected animals and 87% in intraperitoneally injected animals (Fig. 6, B and D) . Tumor growth was static in siID4-treated cohorts for 30 days after the termination of TPN treatment (Fig. 6B) . In contrast, TPN/siGFP or TP-LyP-1 carrier had no effect on ID4 and did not prevent further tumor growth. We also found that both methods of TPN/siID4 injection induced a significant increase in CDKN1A (p21 WAF1/CIP1 ) transcript levels ( Fig. 6C) , a known target of ID4 in mediating cell cycle arrest (28) . Residual TPN/siID4-treated tumors exhibited significant apoptosis (Fig. 6E) .
We then tested whether TPN/siID4 could induce therapeutic activity in mice harboring disseminated tumors. We established orthotopic OVCAR-8 tumors, confirmed intra-abdominal dissemination 3 weeks after implantation, and then initiated intraperitoneal injection of TPN every 3 days for 30 days. The tumor burden in mice that received TPN/siID4 remained low compared to controls (Fig. 7A  and fig. S7A ), and 80% of the recipients of TPN/siID4 (intraperitoneal) survived more than 60 days, even after the nanocomplex treatments ceased at day 50 (Fig. 7B) . After 40 days, disseminated tumors and hemorrhagic ascites were present in control cohorts ( fig. S7B ), but there was no visible tumor lesions in four of five TPN/siID4-treated mice upon necropsy, indicating tumor regression. Histological analysis of the single visible remnant tumor in an siID4-treated animal revealed significant reduction in ID4 levels relative to tumors from the three control cohorts and increased apoptosis in the tumor parenchyma (Fig. 7C and  fig. S7C ).
The versatility of TPN for direct target comparison was demonstrated by treating mice bearing OVCAR-8 tumors with TPN carrying siRNA against Claudin-3 (CLDN3), a recently reported potential ovarian siRNA target (29) . TPN/siCLDN3 led to initial reduction of tumor growth compared to controls treated with saline or TP-LyP-1 carrier alone but was unable to achieve sustained growth suppression compared to TPN/siID4 treatments ( fig. S7D ).
Side effects of TPN administration in vivo
In some cases, apparent therapeutic effects of RNAi may be confounded by non-sequence-specific innate immune responses (30) . Therefore, we independently measured serum levels of interferon-a, tumor necrosis factor-a, and interleukin-6 in immunocompetent mice after administering various TPN-based siRNA formulations and failed to observe induction of these cytokines in animals that received TPN/siID4. By comparison, mice that received an immunostimulatory siRNA, sibgal-728 (30), complexed to either Lipofectamine or TP-LyP-1 were positive controls for nonspecific immunostimulation ( fig. S8A ). Moreover, we did not observe deleterious effects on animal weight in two ovarian tumor models ( fig. S8B ) or evidence of macro- 
DISCUSSION
Current genome characterization efforts will eventually provide insight into the genetic alterations that occur in most cancers and may define new therapeutic targets. However, most epithelial cancers harbor hundreds of genetic alterations as a consequence of genomic instability. For example, whereas recurrent somatic alterations occur in a small number of genes in high-grade ovarian cancers, ovarian cancer genomes are characterized by multiple regions of copy number gain and loss involving at least 1825 genes. This genomic chaos complicates efforts to identify biologically relevant mutations critical for tumor maintenance.
To isolate which recurrent genetic alterations are involved in cancer initiation, tumor maintenance, and/or metastasis, functional assays can be performed after systematic manipulation of the candidate oncogenes. We have combined results from Project Achilles (2), a largescale screening effort to identify genes essential for proliferation and survival in human cancer cell lines with genome characterization of high-grade ovarian cancers. Using this approach, we identified an oncogene candidate, ID4, which was amplified in 32% of high-grade serous ovarian cancers. ID4 is overexpressed in a large fraction of high-grade serous ovarian cancers, and ovarian cancer cell lines that overexpress ID4 are highly dependent on ID4 for survival and tumorigenicity. Expression of ID4 at levels corresponding to those observed in patient-derived samples induced transformation of immortalized ovarian and FT epithelial cells. Our observations credential ID4 as an ovarian cancer oncogene and suggest that ID4 is one of a growing class of lineage-restricted transcriptional factor oncogenes in human epithelial cancers.
Like other ID family proteins, ID4 binds to and regulates the activity of E protein transcription factors such as transcription factors 3 and 12 (TCF3 and TCF12). Indeed, we found that ID4 regulates cell proliferation in part through its effects on p21
. In addition, the transcriptional program induced by ID4 in ovarian epithelial cells was similar to that induced by HOXA9. Although it is clear that ID4 regulates the expression of many genes, we found that suppression of Intensity values are normalized to that of saline controls. Data are averages ± SD (n = 5 per treatment group). **P < 0.01, ***P < 0.001, one-way ANOVA.
HOXA9 abrogated ID4-induced cell transformation. HOXA9 is known to regulate normal hematopoiesis by controlling differentiation, proliferation, and self-renewal (31), and overexpression of HOXA9 or HOXA9-NUP98 in hematopoietic precursors promotes the development of leukemias (32) . In addition, HOXA genes have been shown to play essential roles in specifying regional differentiation of the Müllerian duct into oviduct, uterus, cervix, and vagina (33) . Although previous work has shown that manipulation of ID1, ID2, or ID3 expression induces compensatory changes in other ID family members, we found that expression of ID4, but not that of the other ID family members, induced cell transformation in ovarian epithelial cells. Because amplifications involving other ID family members have not been observed in ovarian cancers, it appears that ID4 plays a unique role in the transformation of this tissue type. Collectively, these findings suggest that inappropriate overexpression of ID4 may contribute to transformation by affecting both p21 WAF1/CIP1 and HOXA9 transcriptional programs that affect differentiation and proliferation programs in the ovary. Nevertheless, further mechanistic studies will be necessary to understand the biology of the new oncogene ID4 and its downstream target, HOXA9.
To credential ID4 as a therapeutic target in human ovarian cancer, we showed that a tandem peptide with both a membrane-translocating domain (TP) and a tumor-penetrating domain (LyP-1) condensed siRNA into nanocomplexes (TPN) that, upon systemic administration into ovarian tumor-bearing mice, penetrated the tumor parenchyma and silenced ID4 in cells of interest (Fig. 5C ). Treatment with TPN/siID4 suppressed the growth of ovarian tumors and significantly improved host survival. Previous approaches using inducible shRNAs to evaluate potential cancer targets were time-consuming and required extensive manipulation of cell lines in vitro (34, 35) . Therefore, we favor this modular, tumor-specific, tumor-penetrating approach that delivers siRNA systemically. TPNs are biodegradable and did not elicit innate immune responses upon systemic delivery, enabling repeated administration for tumor regression studies.
Other methods for siRNA delivery include covalent coupling of siRNA to carriers, but this formulation process requires specialized chemically reactive siRNA and purification steps, obviating the modular "mix and dose" paradigm motivated by the volume of emerging genomic targets (36) . Targeted siRNA delivery has been accomplished in specialized populations such as immune cells, neurons, and hepatocytes; however, these methods are not generalizable across tissue types. Elsewhere, siRNA has been targeted to tumors but not in a tumor-penetrating fashion (5). For example, tumor endothelium has been targeted using RGD-specific nanoparticles; however, this approach does not enable silencing in parenchymal tumor cells, such as those identified with genetic alterations in TCGA (1). Passive targeting (for example, the EPR effect) of siRNA in neutral liposomes, in complexes with CPP such as TAT, or transferrin-targeted cyclodextrin has also been described in mouse models and recently in humans (37, 38) , but tumor penetration remained a challenge (39). Our TPN technology represents an important therapeutic paradigm for systemic targeting of undruggable proteins that are essential in parenchymal tumor maintenance.
Although we have focused on ID4, TPN delivery technology can be generalized to other cancers. Approximately 60 of 81 samples across 10 tumor types exhibit surface expression of p32 (20) . Our modular siRNA delivery platform can leverage other homing peptides, such as iRGD, to expand the number and types of TPN-targeted parenchymal tumor cells. More generally, ongoing cancer genome characterization efforts combined with comprehensive functional studies will narrow the number of potential cancer targets, but putative oncogenes will still require validation in vivo. TPN offers an efficient platform to verify which genes are critical to cancer initiation and maintenance.
Our studies demonstrate that TPN exhibits both specificity and pharmacokinetic properties that may provide a platform for human siRNA delivery. To reach this goal, further development is required, such as optimization of circulation time, assessment of efficacy in higher fidelity models of cancer, and reformulation to increase knockdown efficiency and reduce dosing. The path to translating TPN to the clinic will require multispecies toxicity testing, assessment of repeated dosing and potential immunostimulation, and evaluation of the prevalence of the tumor penetration pathway and p32 in human tumors and metastases.
In summary, we developed a targeted TPN capable of precisely delivering siRNA into the tumor parenchyma, and have combined this technology with large-scale methods to credential ID4 as an oncogene target in ovarian cancer. Because large-scale efforts to characterize all cancer genomes accelerate, this capability illustrates a path to identify genes that are altered in tumors, validate those that are critical to cancer initiation and maintenance, and rapidly evaluate in vivo the subset of such genes amenable to RNAi therapies and clinical translation.
MATERIALS AND METHODS
Pooled shRNA library screen shRNA constructs are available through Sigma-Aldrich. Genome-scale pooled shRNA screens in 102 cancer cell lines were performed with a lentivirally delivered pool of 54,020 shRNAs targeting 11,194 genes. Each cell line was infected in quadruplicate and propagated for at least 16 population doublings (2) (Supplementary Materials and Methods). The abundance of shRNAs relative to the initial DNA plasmids was measured by microarray hybridization and normalized with dChip and GenePattern modules before identifying essential genes.
Analysis of TCGA data
Copy number alterations were determined by TCGA on 489 primary ovarian tumors with Illumina 1M-Duo arrays, and recurrently amplified regions were analyzed by GISTIC 2.0 (40) with 99% confidence intervals (Supplementary Materials and Methods). For each amplified gene, the distribution of shRNA scores were converted to z scores, and shRNAs with a P < 0.05 were identified.
Cell culture
To determine the effects of shRNA on cell proliferation, we performed six replicate infections and determined viability 5 days later (Supplementary Materials and Methods). Transformation was determined by introducing ID4 into IOSE-M (41) and FTSEC-M (FT secretory epithelial) cells (16) and performing anchorage-independent growth experiments or monitoring tumor formation by injecting cells subcutaneously into BALB/c immunodeficient mice (Charles River).
Gene expression profiling
Gene expression profiling was performed in triplicate on Affymetrix HG-U133A_2 GeneChips. Processed data from microarray experiments
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were analyzed with GSEA (42) (Supplementary Materials and Methods).
Tumor-penetrating nanocomplexes
The tandem peptide library was synthesized by standard Fmoc (9-fluorenyl methoxycarbonyl) solid-phase peptide synthesis and purified by high-performance liquid chromatography (Supplementary Materials and Methods). Peptides were mixed with siRNA at a molar ratio of 20:1. Nanocomplexes were incubated over cell culture for 4 hours, and cells were harvested 48 hours later for characterization of gene knockdown. For competition with free LyP-1, unlabeled LyP-1 peptide was added for 1 hour before TPN treatment.
Therapeutic studies in mice
TPNs carrying ID4-specific siRNA were administered intravenously or intraperitoneally to NCr/nude mice bearing either subcutaneous OVCAR-4 or intraperitoneal disseminated OVCAR-8 tumors, respectively. Tumor burdens were monitored through caliper measurements or bioluminescence imaging (Supplementary Materials and Methods).
Statistical analysis
Unless otherwise indicated, one-way ANOVA was used (GraphPad). P < 0.05 was considered statistically significant. Fisher's exact test was used for tumor formation assays. Two-tailed Student's t test was used for pairwise comparisons. A log-rank test was performed for animal survival studies. Table S1 . List of amplified genes with at least one shRNA that score with a P < 0.05. The PDF file includes:
SUPPLEMENTARY MATERIALS
Materials and Methods Table S1 . List of amplified genes with at least one shRNA that score with a P < 0.05. Table S2 . Sequence and characterization of tandem peptides.
Analysis of TCGA primary tumor data
Regions of copy number amplification identified by Genomic Identification of Significant Targets in Cancer (GISTIC) analyses were used from the TCGA study on high-grade serous ovarian cancer (1). All RefSeq genes within these regions of amplification (n = 1825) were identified and cross referenced with genes interrogated in the screening library (n = 778). All primary high-grade serous ovarian cancer data were downloaded from the TCGA portal (http://tcga-data.nci.nih.gov/tcga). The frequency of amplification for ID4, KRAS, ERBB3, and SKP2 genes was determined by using a threshold of log 2 copy number ratio > 0.3 within a subset of tumors in TCGA project (n = 345). Screenshots of the same tumor data were taken using the Integrative Genome Browser (http://www.broadinstitute.org/igv).
Analysis of shRNA screening data
Raw .CEL files from custom Affymetrix barcode arrays were processed with a modified version of dCHIP software. The GenePattern module 'shRNAscores' was used to calculate the log fold change scores derived from replicate measurements of the shRNA abundance in each cell line at the conclusion of the screening relative to initial DNA reference pool. This score was adjusted to de-emphasize shRNAs that showed high variability among replicates of the DNA pool. This log fold change score was divided by the s.d. of the DNA pool after it had been mean centered at 1 and floored at 1 to de-emphasize shRNAs that showed high variability among replicates of the DNA pool, which likely arises from technical artifacts including shRNA under-representation in the initial DNA pool or sub-optimal array probe performance. The Gene Pattern module 'NormalizeCellLines' was then used to normalize the adjusted log fold change scores among cell lines by scaling and centering these scores with peak median absolute deviation (PMAD) normalization, a variation of ZMAD. PMAD normalization consisted of, first, centering the shRNA scores per cell line at 0 by subtracting the value of each shRNA from the modeled peak value of the distribution of each cell line. The shRNA scores for each cell line were then rescaled so that each line had similar data ranges by dividing the centered data for each shRNA by the median absolute deviation (MAD).
To identify genes that were both amplified in ovarian tumors and essential in amplified cell lines, each gene identified as amplified in primary ovarian tumors was tested across the entire panel of 102 cell lines screened. For those genes that had 5 or more lines with an amplification of the gene, the median shRNA score for each shRNA in the pool was calculated and used to convert shRNA scores to z-scores. Amplified genes that had mapped shRNAs with a P < 0.05 were identified.
Cell culture and generation of stable cell lines
All human cancer cell lines were cultured in previously described media supplemented with 10% fetal bovine serum (FBS, Sigma) (2). Immortalized human ovarian surface epithelial cells (IOSE) µg/ml polybrene. After the incubation, medium was replaced with fresh medium for another 24 h before selection in media containing 2 µg/ml of puromycin for 2 days, 10 µg/ml of blasticidin for 4 days, or 800 µg/ml of neomycin for 5 days. TRCC0019251729).
Plasmids

Peptides and siRNAs
The Institute. Probes were aligned to a transcript database consisting of RefSeq (36.1) and complete coding sequences from GenBank (v.161). Gene-centric expression values were generated for every gene with at least 5 probes. Data for each experiment was normalized and summarized using robust multichip average (RMA), then logged and row-normalized.
Gene Set Enrichment Analysis (GSEA)
Processed expression data from either the shID4 or ID4 overexpression experiments was analyzed using GSEA v2.06 (http://www.broadinstitute.org/gsea/) (44). For the shRNA experiments, we compared expression profiles derived from OVCAR-8 cells infected with a control shGFP and OVCAR-8 cells infected with shID4. For overexpression experiments, IOSE-M cells expressing a control vector were compared to cells overexpressing ID4. GSEA was run using the default settings, except for the following; permutations were based on the gene sets, not on phenotype and data was not collapsed to gene symbols (this was done prior to GSEA).
We additionally identified gene sets enriched in particular populations of ovarian tumor samples. GSEA comparing 109 samples with amplified ID4 (log 2 copy number ratio >0.3) vs. 81 non-amplified ID4 samples (log 2 copy number ratio <0) was performed using expression data from primary ovarian samples with matched copy number from TCGA.
Fluorescence in situ hybridization (FISH)
BAC RP11-72I11 clone containing ID4 (Invitrogen) was labeled with Digoxigenin (Roche) using BioPrime labeling mix (Invitrogen). A reference probe specific for the centromeric region Slides containing metaphase chromosomes were pretreated with 1:25 Digest-All III (Invitrogen) at 37 o C for 6 min before fixation in 10% buffered formalin for 1 min at room temperature. Slides were dehydrated for 2 min each in 70%, 85%, 95% and 100% ethanol at room temperature. Probes were prepared by mixing 2 µl of each labeled probe, 1 µl Cot-1 DNA
(1 mg/ml; Invitrogen), and 11 µl of hybridization buffer. Probes were applied to air-dried slides;
coverslips were applied and sealed with rubber cement. These preparations were denatured at 
Gel-shift and stability assays
For the gel-shift assay, siRNA was mixed with peptide at specified molar ratios in phosphate buffered saline for 10-15 min at room temperature. The mixture was analyzed by non-denaturing gel electrophoresis using a 15% acrylamide gel for siRNA, stained with SYBR-Gold, and visualized under UV light. For the siRNA stability assay, siRNA (100 pmol) was mixed with TPLyP-1 (2 nmol) in PBS for 10-15 min at room temperature. Naked siRNA or TPN was then added to 100% murine serum (10:1 v/v) and incubated at 37°C for the indicated times, after which the RNA was extracted and precipitated, separated on a 15% TBE gel, stained with SYBR-Gold, and visualized under UV light.
Peptide uptake and gene silencing
For the initial screen, HeLa cells expressing GFP were cultured in 96-well plates to ~40-60%
confluence. siRNA (0-100 nM) was incubated with 20-fold molar excess of tetramethylrhodamine-labeled tandem peptides in PBS for 10-15 min at room temperature, h later using Celltiter-Glo assays (Promega) according to manufacturer's instructions.
Anchorage-independent growth assay
Growth in soft agar was determined by plating 1×10 4 cells in triplicate in 5 ml of medium containing 0.35% Noble agar (BD Biosciences) which was placed on top of 4 ml of solidified 0.7% agar. Colonies greater than 100 µm in diameter were counted 4 weeks after plating. 
Real-time quantitative RT-PCR
Total RNA was extracted with Trizol reagent (Invitrogen). Total RNA (4 µg) for each sample was used to synthesize the first-strand cDNA by using Oligo(dT) 20 Blood was drawn retroorbitally and siRNA fluorescence was measured using the Odyssey imaging system (Li-COR Biosciences). Organs were harvested and imaged 6 h after injection.
Tumor explants were examined at high resolution (84 µm) using the Odyssey imager with an excitation wavelength of 785 nm. To study time-dependent homing and tumor, TPNs carrying Treatments were initially twice weekly for 14 days. Upon observing suppression in tumor growth, treatment frequency was reduced to once weekly for 3 more weeks to limit possible side effects and toxicity. On day 60, tumors and organs were harvested for immunohistochemical analyses.
Whole-animal BLI was performed every 3 days. Mice were anesthetized using isofluorane, injected with 150 mg/kg D-luciferin (Promega), and imaged 10-15 min after injection once the signal peaked.
Immunostaining and analysis
Tumors were harvested and fixed in 4% paraformaldehyde at 4°C overnight, soaked in 30% (w/v) sucrose for 24 h, then snap frozen. Rat anti-mouse CD31 (1:50, BD PharMingen) and a polyclonal anti-p32 antibody were used for immunohistochemical staining. Rat or rabbit IgGs were used as isotype controls. Sections were washed and detected with Alexa Fluor 488 goat anti-rat or anti-rabbit IgG (1:1000; Invitrogen). The slides were counterstained with DAPI and mounted on glass slides for microscopic analysis. At least three images from representative microscopic fields were analyzed for each tumor sample using the ImageJ software.
Immunogenicity studies in mice
Balb/c immunocompetent mice were injected intraperitoneally with TPN carrying siID4, siGFP, siLUC, or siβgal-728 at 5 mg siRNA/kg. siβgal-728 was encapsulated in Lipofectamine. Table S2 . Sequence and characterization of tandem peptides. The myr-prefix denotes Nterminal myristoylation. Lysine (K) residues were labeled with a fluorophore (TAMRA). Mean diameter was based on DLS measurements in PBS. For zeta-potential and diameter, n = 4 independent measurements. Peptide abbreviations are as follows: (dR) n , oligoarginine, where n is the number of d-Arginine residues; PEN, penetratin; TAT, HIV TAT (48-60); TP, transportan; VP22, HSV-1 VP22 protein.
SUPPLEMENTARY TABLES
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